Akili, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported a rise in third-quarter revenue to $702,000, from $114,000 in the second quarter of this year, which the company attributes to the continued growth of its adult ADHD offering EndeavorOTC.
The company reported total operating expenses of $18.8 million for the third quarter, compared to $15...
Akili Interactive, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported its second-quarter earnings since expanding into the adult ADHD market in June with the release of its over-the-counter offering EndeavorOTC.
The Boston-based company reported $114,000 in revenue for the second quarter of 2023 compared to $113,000 in the first quarter of this...
Global healthcare company AmerisourceBergen has announced a strategic partnership with business-to-business telehealth provider SteadyMD, beginning with the companies cocreating and piloting a telehealth offering for independent community pharmacies dubbed Test to Treat.
The Test to Treat model allows individuals to be tested for an illness or condition at an independent pharmacy and then consult...
CHICAGO — During the Venture Connect panel on demystifying digital therapeutics at the 2023 HIMSS Global Health Conference & Exhibition here on Tuesday, panelists provided insights into the state of investments in digital therapeutics, the barriers to adoption, challenging existing standards of care and how success in the sector requires patience and persistence.
"Very recently [investment]...
Akili Interactive, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported its first full-year earnings since going public last year.
The company reported $323,000 in revenue for 2022 compared with $538,000 for 2021. Akili said 2022 revenue was entirely made up of funds earned from sales of EndeavorRx, its therapeutic that received FDA clearance for...
Akili Interactive, maker of a video game-like digital therapeutic for children with ADHD, announced last week it will cut about 30% of its staff.
The layoffs, which will affect 46 workers, are expected to be completed by the end of the first quarter, according to a filing with the Securities and Exchange Commission.
Akili will also put some programs related to cognitive health outside of ADHD on...
Akili Interactive hit the public markets in August, bringing in cash the company will use to launch its video game digital therapeutic for children with ADHD later this year.
Akili's product, dubbed EndeavorRx, is prescription software for kids ages 8 to 12 who have attention issues. It received FDA De Novo clearance in 2020 after years waiting for the agency green light, though a nonprescription...
Akili, maker of a video game-like digital therapeutic for children with ADHD, hit the public markets Monday after wrapping up a merger with special-purpose acquisition company Social Capital Suvretta Holdings Corp. I.
The newly public digital health firm said the deal brought in more than $163 million before paying transaction expenses and advisory fees. Akili plans to use the cash to launch...
Akili Interactive, maker of a video-game-like digital therapeutic for treating pediatric ADHD, announced nominees for its board of directors once the company goes public.
The nominees for the public board include William "BJ" Jones, a chief commercial officer at Biohaven Pharmaceuticals; Christine Lemke, co-CEO of Evidation Health; Ken Ehlert, former chief scientific officer at UnitedHealth Group...
Adults with depression that used Akili's video game-like intervention improved their cognitive functioning and sustained attention, according to a small study published in The American Journal of Psychiatry.
Researchers did not find any statistically significant difference in depression symptoms between patients in the control and intervention groups, though both groups did statistically improve...
